Historically, managing C3G relied on off-label immunosuppressive agents and corticosteroids, which offered limited disease-specific efficacy. While the recent approvals of Fabhalta and Empaveli/Aspaveli provided the first targeted options, these therapies carry significant safety warnings regarding life-threatening bacterial infections. This clinical gap has left patients and providers seeking safer, more convenient alternatives, particularly those that might eventually offer oral administration.
In section Releases
New Pipeline Drugs Target $1 Billion Complement 3 Glomerulopathy Market
The treatment landscape for Complement 3 Glomerulopathy (C3G) is undergoing a significant shift as pharmaceutical developers race to move beyond traditional immunosuppressants. With the global market valued at approximately $1 billion in 2025, four distinct investigational therapies are emerging to challenge recently approved standards of care.
DelveInsight projects the C3G market across the 7MM region will grow at a 28% compound annual growth rate through 2036. Current development efforts are focused on novel mechanisms:
- Zaltenibart (Novo Nordisk/Omeros): A MASP-3 inhibitor that recently gained Rare Pediatric Disease Designation.
- KP104 (Kira Pharmaceuticals): A bifunctional biologic designed to inhibit both alternative and terminal complement pathways simultaneously.
- ARO-C3 (Arrowhead Pharmaceuticals): An RNAi therapeutic that reduces liver-derived C3 production.
- CPV-104 (Eleva): A recombinant human Factor H therapy currently undergoing clinical evaluation to clear kidney C3 deposits.
Comments (0)
No comments yet. Be the first!